Spruce Biosciences Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Spruce Biosciences Stock Summary

Spruce Biosciences competes with Inozyme Pharma, Day One, Terns Pharmaceuticals, Eledon Pharmaceuticals, and Hookipa Pharma. Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California. Spruce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.

Spruce Biosciences Key Financial Ratios

Spruce Biosciences Key Balance Sheet Accounts

Spruce Biosciences Key Income Statement Accounts

Spruce Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Spruce Biosciences's current stock value. Our valuation model uses many indicators to compare Spruce Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spruce Biosciences competition to find correlations between indicators driving Spruce Biosciences's intrinsic value. More Info.Spruce Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Spruce Biosciences' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Spruce Biosciences' earnings, one of the primary drivers of an investment's value.

Spruce Biosciences Systematic Risk

Today, most investors in Spruce Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Spruce Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Spruce Biosciences growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Spruce Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Spruce Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Spruce Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Spruce Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Spruce Biosciences's daily price indicators and compare them against related drivers.

When running Spruce Biosciences' price analysis, check to measure Spruce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spruce Biosciences is operating at the current time. Most of Spruce Biosciences' value examination focuses on studying past and present price action to predict the probability of Spruce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spruce Biosciences' price. Additionally, you may evaluate how the addition of Spruce Biosciences to your portfolios can decrease your overall portfolio volatility.